ArticleTaiwan journal of ophthalmology
Cysteine-rich 61 mediates inflammation by the NF-κB/cyclooxygenase-2 pathway in RF/6A cells.
Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCysteine-rich 61 (Cyr61) may enhance angiogenesis and inflammation in diabetic retinopathy (DR). Cyclooxygenase-2 (COX-2) is an immediate-early gene product of inflammation and it also plays an important role in developing DR. We aim to investigate the effects of Cyr61 on COX-2 expression in chorioretinal vascular endothelial (RF/6A) cells and to study the possible signal transduction pathway and the transcriptional mechanisms. MATERIALS AND
methodsThe effects of Cyr61 on COX-2 expression were evaluated via determining the mRNA, protein, and prostaglandin (PG) E2 levels of RF/6A cells. To examine the pathway in this process, RF/6A cells were pretreated with integrin ανβ3-blocking antibodies, a FAK inhibitor (PF573228), a PI3K inhibitor (LY294002), and an Akt inhibitor (A6730), respectively. Electrophoretic mobility shift assays (EMSAs) and luciferase reporter assays were applied to assess if NF-κB was involved in this response.
resultsCyr61 stimulated the expression of COX-2 at the mRNA, protein, and PGE2 levels in a dose-dependent and time-dependent manner. Both COX-2 and PGE
conclusionsInduction of COX-2 by Cyr61 is mediated through the activation of the integrin ανβ3, FAK, PI3K/Akt, and NF-κB pathways in RF/6A cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.